Company / Revenue
Cue Biopharma, Inc. Revenue History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$27.5M
FY2025
5-year range
$1.2M / $27.5M
FY2021-FY2025
Trend
+195.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has increased for 3 consecutive years, from $1M in FY2022 to $27M in FY2025.
Based on SEC 10-K filings.
$27M in FY2025 with a 5-year CAGR of +51.4%.
Improved from $5M to $27M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +180.5%
- 5-Year CAGR
- +51.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- Cue Biopharma, Inc.'s revenue has grown for 3 consecutive years.
- 5-year CAGR of +51.4%, indicating consistent growth.
- In FY2025, revenue increased 195.7% year-over-year.
- Lowest revenue in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $27.5M | +195.7% |
| FY2024 | $9.3M | +69.2% |
| FY2023 | $5.5M | +341.0% |
| FY2022 | $1.2M | -91.7% |
| FY2021 | $14.9M | +332.0% |
| FY2020 | $3.5M | +202.7% |
| FY2019 | $1.1M | +0.0% |
| FY2018 | $1.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026